Dear Colleague:

IIn the ten years since its inception, American Conference Institute’s (ACI’s) Paragraph IV Disputes conference has become the pharmaceutical industry’s leading forum on Hatch-Waxman litigation. Each spring, the “who’s who” of Hatch-Waxman litigators and industry decision makers, as well as members of the judiciary and key government representatives gather in New York City at this conference to assess the implications and imprimaturs of court cases, legislation, and industry behaviors which affect the patent endgame and the pursuit of related profits. This “must-attend” event serves the legal and business needs of both branded and generic drug makers by providing invaluable “take aways” for legal strategies and cost-analysis for every facet of this complex litigation from pre-suit considerations to case filings through final adjudication.

In the course of the next eighteen months, the industry will scale the next escarpments of the proverbial patent cliff which will bring an additional 90 billion dollars in patent losses when block buster drugs such as Nexium, Lunesta, Abilify, Crestor and Restasis all go off patent. This will result in increased ANDA litigation between brands and generics, as well as increased challenges among generics vying to be the first to obtain the highly coveted prize of 180-day exclusivity. However, there will also be new challenges to face. Brands and generics must assess of the impact and utilization of PTO proceedings which have provided alternative and parallel forums to the Federal Courts. Then, there is still the uncertainty of how these cases can properly be settled, which may add to the already astronomical cost of these litigations as settlements may be both legally and economically infeasible.

In response to these challenges, ACI is pleased to present this year’s 10th Anniversary Paragraph IV Disputes conference. We welcome you to join our exceptional faculty and your peers as we explore not only the latest legal nuances affecting the essentials of Hatch-Waxman litigation, but also new dilemmas affecting pharmaceutical patent sustainability and vulnerability.
Clearly, there is not a moment to lose in this ruthless endgame of no-holds bar litigation. Do not be left behind.

Register today by calling 1-888-224-2480, faxing your registration form to 1-877-927-1563 or online.

We look forward to seeing you in New York this April.

Very truly yours,


Lisa J. Piccolo, Esq.
Senior Industry Manager, Life Sciences and Health Care
American Conference Institute

For Information on Sponsorship please contact Esther Fleischhacker